DDInter813 DDInter1376
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Gemifloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Gemifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Gemifloxacin {u} (Compound) causes {v} (Side Effect) Tendon rupture
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Triamcinolone
Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Gemifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Gemifloxacin (Compound) causes Tendon rupture (Side Effect)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Gemifloxacin may lead to a major life threatening interaction when taken with Nilotinib
Gemifloxacin may lead to a major life threatening interaction when taken with Triamcinolone